Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Location
321 Harrison Avenue, Suite 900, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442 % -21.3%
Debt-to-equity 63.2 % +2.9%
Return On Equity 8.28 %
Return On Assets 5.07 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.1M shares
Common Stock, Shares, Outstanding 61.8M shares +0.67%
Entity Public Float 199M USD -15.1%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 82.4M shares +0.47%
Weighted Average Number of Shares Outstanding, Diluted 82.4M shares +0.47%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 138M USD +26%
General and Administrative Expense 34.6M USD +1.52%
Operating Income (Loss) 8.51M USD -24.3%
Nonoperating Income (Expense) 13.4M USD +34.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 22M USD -27.2%
Income Tax Expense (Benefit) 1.01M USD +163%
Net Income (Loss) Attributable to Parent 20.9M USD -13.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 208M USD +65.9%
Cash, Cash Equivalents, and Short-term Investments 391M USD
Accounts Receivable, after Allowance for Credit Loss, Current 9M USD
Assets, Current 402M USD +60%
Property, Plant and Equipment, Net 27.6M USD -12.2%
Operating Lease, Right-of-Use Asset 25.1M USD -8.4%
Other Assets, Noncurrent 411K USD +158%
Assets 460M USD +45.9%
Accounts Payable, Current 14.5M USD +265%
Employee-related Liabilities, Current 7.26M USD +8.31%
Liabilities, Current 61.4M USD +47.6%
Operating Lease, Liability, Noncurrent 35.9M USD -10.3%
Liabilities 214M USD +95.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.25M USD -39.8%
Retained Earnings (Accumulated Deficit) -431M USD +4.63%
Stockholders' Equity Attributable to Parent 246M USD +19.7%
Liabilities and Equity 460M USD +45.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.5M USD -19.2%
Net Cash Provided by (Used in) Financing Activities 246K USD
Net Cash Provided by (Used in) Investing Activities -100M USD -1117%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 61.8M shares +0.67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -146M USD -419%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 213M USD +63.5%
Deferred Tax Assets, Valuation Allowance 72.2M USD +32.5%
Deferred Tax Assets, Gross 83.1M USD +24.7%
Depreciation 8.33M USD +5.35%
Payments to Acquire Property, Plant, and Equipment 1.59M USD +14.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 20M USD -14.6%
Property, Plant and Equipment, Gross 53.1M USD +6.79%
Operating Lease, Liability, Current 4.24M USD +16.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD +19.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD -100%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 637K USD +10.2%
Deferred Tax Assets, Net of Valuation Allowance 11M USD -10%
Share-based Payment Arrangement, Expense 19M USD +1.92%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%